Advertisement
GERN vs SLDB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Hold and SLDB is a Hold.
GERN sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for GERN moved below the 200-day moving average on September 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GERN as a result. In 85 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
GERN moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GERN crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for GERN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GERN's RSI Indicator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 70 cases where GERN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for GERN just turned positive on October 08, 2026. Looking at past instances where GERN's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.
Following a +2.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in 170 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
GERN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. GERN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.674) is normal, around the industry mean (26.782). GERN has a moderately high P/E Ratio (220.000) as compared to the industry average of (43.395). Projected Growth (PEG Ratio) (16.670) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (4.250) is also within normal values, averaging (437.542).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for SLDB turns negative, indicating new downward trend
SLDB saw its Momentum Indicator move below the 0 level on September 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 70 similar instances where the indicator turned negative. In 63 of the 70 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SLDB turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 39 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SLDB moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SLDB crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for SLDB entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in 205 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
SLDB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.087) is normal, around the industry mean (26.782). P/E Ratio (0.155) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
GERN | SLDB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 25 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 74 | 64 | |
P/E GROWTH RATING 1..100 | 60 | 3 | |
SEASONALITY SCORE 1..100 | n/a | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SLDB's Valuation (25) in the Biotechnology industry is significantly better than the same rating for GERN (100). This means that SLDB’s stock grew significantly faster than GERN’s over the last 12 months.
SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GERN (100). This means that SLDB’s stock grew similarly to GERN’s over the last 12 months.
GERN's SMR Rating (97) in the Biotechnology industry is in the same range as SLDB (98). This means that GERN’s stock grew similarly to SLDB’s over the last 12 months.
SLDB's Price Growth Rating (64) in the Biotechnology industry is in the same range as GERN (74). This means that SLDB’s stock grew similarly to GERN’s over the last 12 months.
SLDB's P/E Growth Rating (3) in the Biotechnology industry is somewhat better than the same rating for GERN (60). This means that SLDB’s stock grew somewhat faster than GERN’s over the last 12 months.
| GERN | SLDB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| Momentum ODDS (%) | 7 days ago 88% | 6 days ago 90% |
| MACD ODDS (%) | 2 days ago 79% | 6 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| Advances ODDS (%) | 6 days ago 77% | 27 days ago 81% |
| Declines ODDS (%) | 2 days ago 79% | 2 days ago 89% |
| BollingerBands ODDS (%) | 6 days ago 76% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GERN’s FA Score shows that 0 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).
- GERN’s FA Score: 0 green, 5 red.
- SLDB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GERN’s TA Score shows that 5 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).
- GERN’s TA Score: 5 bullish, 6 bearish.
- SLDB’s TA Score: 4 bullish, 6 bearish.
Price Growth
GERN (@Biotechnology) experienced а -0.83% price change this week, while SLDB (@Biotechnology) price change was -15.90% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.49%. For the same industry, the average monthly price growth was -19.00%, and the average quarterly price growth was -19.88%.
Reported Earning Dates
GERN is expected to report earnings on Nov 11, 2026.
SLDB is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-8.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
SLDB and
Correlation & Price change
A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To SLDB | 1D Price Change % | ||
|---|---|---|---|---|
| SLDB | 100% | -13.26% | ||
| EDIT - SLDB | 60% Loosely correlated | -11.09% | ||
| CRBU - SLDB | 56% Loosely correlated | -5.41% | ||
| RCKT - SLDB | 54% Loosely correlated | -7.26% | ||
| IMTX - SLDB | 53% Loosely correlated | -5.27% | ||
| BEAM - SLDB | 53% Loosely correlated | -2.79% | ||
More | ||||